GlassScriptPhysician profile
Karng S Log
NPI 1932310034
$3,888.46
in general payments reported to CMS, 2019-2025
40 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $706 · 2023: $2,289 · 2024: $316 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,545 · Consulting Fee: $1,170 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,544.71 |
| Consulting Fee | $1,170.00 |
| Education | $268.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $1,187.86 | 2023 | Rybrevant, Balversa |
| Janssen Biotech, INC. | $393.31 | 2022-2025 | Rybrevant, Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $343.73 | 2023-2024 | Opdivo, Augtyro |
| Genzyme Corporation | $207.21 | 2021-2023 | |
| Karyopharm Therapeutics INC. | $153.83 | 2022-2023 | Xpovio |
| Cti Biopharma Corp. | $148.78 | 2023 | Vonjo |
| Seagen INC. | $117.79 | 2021-2023 | Tukysa |
| Incyte Corporation | $115.79 | 2022-2023 | Monjuvi |
| Tempus Ai, INC | $107.83 | 2025 | Xt Cdx |
| Amgen INC. | $97.36 | 2022-2023 | Vectibix, Nplate, Xgeva |
| Astrazeneca Pharmaceuticals LP | $93.98 | 2023-2024 | Tagrisso |
| Sobi, INC | $91.85 | 2022-2023 | |
| Pharmacosmos Therapeutics INC. | $69.92 | 2022-2023 | Monoferric |
| Argenx US, INC. | $55.50 | 2025 | |
| Novocure INC. | $50.22 | 2022 |
Show all 37 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karng Log listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.